{"name":"Suzhou Alphamab Co., Ltd.","slug":"suzhou-alphamab-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"KN057","genericName":"KN057","slug":"kn057","indication":"Advanced or metastatic solid tumors (in combination with other immunotherapies)","status":"phase_3"},{"name":"KN060 Low","genericName":"KN060 Low","slug":"kn060-low","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"KN057 dose Ⅱ","genericName":"KN057 dose Ⅱ","slug":"kn057-dose","indication":"Other","status":"phase_2"},{"name":"KN060 Hight","genericName":"KN060 Hight","slug":"kn060-hight","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"KN057","genericName":"KN057","slug":"kn057","phase":"phase_3","mechanism":"KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (in combination with other immunotherapies)"],"catalyst":""},{"name":"KN057 dose Ⅱ","genericName":"KN057 dose Ⅱ","slug":"kn057-dose","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"KN060 Hight","genericName":"KN060 Hight","slug":"kn060-hight","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KN060 Low","genericName":"KN060 Low","slug":"kn060-low","phase":"phase_2","mechanism":"KN060 Low is a monoclonal antibody targeting PD-L1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQbjhoQ0xTNDMzaUdLNGRTSXNPOTVJNlhUeS1OOEZrVVRmRUttOFRfOFhjZmtCMlJkVTNDUkJFTFE4aDM3aHdOUTFOU2JxUHVFSExPSWhLRGZfeEY5M1hEcUxDbEJNRHJiRVBzUzFuUmtGVTc4MmFDb01BNVFTaDB3NGFoREI3emh6MG1oclpQZWpsd3ljZHhFM3RBWU41TXo0Y18xSi1vSVhJV3BLMVdsWENSd25zemJmUEpGNXdXTjZaSUc1TkZhQ1RVdDFNalZGbFB6R1M1LUJWdllRUGM0NEFyN2FHUjdY?oc=5","date":"2026-03-23","type":"trial","source":"Barchart.com","summary":"Diabetes Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight - Barchart.com","headline":"Diabetes Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-11","type":"pipeline","source":"The Manila Times","summary":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer - The Manila Times","headline":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUDJhd1E3bVdudTM5VS0wN1dyNTdMS0dMbGpmRGFsVlVaNWV4V3VQZGw0RzBQRWlaSFo1bGVJbW9BX2lmYmI4bEh0U3JWRVJnU3RmZnpHZlMwRnJBY0xNRnBhMmUySkxJYlozZUhJWnRNcEQzMndzcVNRcWxMLTVhUkN1NFFOa0pBcXh2aG1pYUVhSEpJOEswUGlmUERIWWg1ZXhLeTBQRkdqQQ?oc=5","date":"2026-01-27","type":"trial","source":"BioWorld News","summary":"Alphamab’s HER2 bispecific hits phase III gastric cancer endpoints - BioWorld News","headline":"Alphamab’s HER2 bispecific hits phase III gastric cancer endpoints","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQTmZpcHBCLWd3VHJRc2JHVVkwb09oaVJPT25wMWVxajZCZ09ZOEpjbHdETU1JeFRHV3RUczlKT1F6NVNLUDRRd2RNY0NBaUpvZS1Xc0NfUC1VSkptd1lWMjhhREUxcGFSTWtNaE5UTUxtb0liaXZPaUpFQVhBbElZT3dmV0p5bEFTSUJ3eG1Vc000LTkwZ3p4ZDB1WQ?oc=5","date":"2026-01-06","type":"deal","source":"BioWorld News","summary":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal - BioWorld News","headline":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNenp4MDZKS2FTTmpqcFJYTHJDTWxkTEo0cGRKWno1SVBjZHluTkgtSmZjX1pVNzZsVXp3QWVmQ0lZdlRUa1pMMHV5cXJnRWtYVkhYQmZHVTY0UEZGSThwOUMzaEVKXzR6c0Nobm9PdkxLYU9pRU94XzdaUmZESkQzOWVPNl80U1liMG1XamY4dUQ2UFh3Q1dGcElXeW9NM2FjeldjWW1HZUE?oc=5","date":"2025-10-21","type":"deal","source":"BioWorld News","summary":"Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline - BioWorld News","headline":"Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPTVBROS02cE8tTzQteXNjWEFSRURwdDVxUXZ6TDlqaE12YXB4UndwV3FCdl9Mc25UeUd6aFdWdThwSXBfYW1EUEVMa1Fsa3RUWGlLNnZYX2xPdDRqVnZ4dVpwa0dXSVE5aHVKVm93aWVXRDlVWWZ4NnBmOEhkTV9haFJXaEZ4R3ZpQmZ5R0w4WkFPQjF0dG44aFcyQ1pIS0psWkxRVkluaEJzTG1fbGI0V0JqMjJjNWFMbnp2bi1mc3h5ZURIbmNfWVI3UnBJTHN3eDZzU0xISUxpVlRWcnFqOC1GVGo5N0NYRlN0aFpab2pub3ZvYVRPZjRPZzM?oc=5","date":"2025-04-07","type":"regulatory","source":"Barchart.com","summary":"Diabetes Pipeline Insights, Clinical Trials Report 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com","headline":"Diabetes Pipeline Insights, Clinical Trials Report 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV0hzT3N1dk10djRZX3Y1TGlNVWhFUGlQWGxvS2VqaHJQekNwQ3NmMnJUUTRXaUJrZjg2ejl4UUJ1aUFKOGhQRm9wOFpyT2hYNUVXdmlfN2NzLWxqb2k5bnM0d2NWX3N0QlRRWGFBRkdfOUI5V2Y2SGdnMlR4bHZ4SE50amdTQ3hXVXVFUHIyODcwNWcwa1E4Z29wbktCaTI4QTVFSFFKekU?oc=5","date":"2024-07-02","type":"trial","source":"BioWorld News","summary":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop - BioWorld News","headline":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQM0pMcGN4VkdXZG9RNjZSUk9scXlyazdtV0dIcDZkNXd4Tm1sVFUyMzF2ZUVCZjBYaWgxWDZZdm1zZFgxdUsyZFJIbmpXb252UWRPUzlocVBqZDJiaVFhcEhZakVBdkFmUlZKMHNKNXVBWHF3MlY0WnlscU90VDdUUERqWTQ1aFdjY2FrREFDMm1OeGVncFlMRWZ3UUV0R3c?oc=5","date":"2021-03-14","type":"pipeline","source":"Frontiers","summary":"Lipidomic Perturbations in Cynomolgus Monkeys are Regulated by Thyroid Stimulating Hormone - Frontiers","headline":"Lipidomic Perturbations in Cynomolgus Monkeys are Regulated by Thyroid Stimulating Hormone","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_2":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}